Zürcher Nachrichten - Ketamine pill treats depression without psychedelic effects: study

EUR -
AED 4.241201
AFN 76.219915
ALL 93.210974
AMD 421.7986
AOA 1060.156793
ARS 1727.958172
AUD 1.63908
AWG 2.081626
AZN 1.959559
BAM 1.954403
BBD 2.32254
BDT 142.738005
BHD 0.43488
BIF 3440.896583
BMD 1.154855
BND 1.478624
BOB 14.004993
BRL 5.916207
BSD 1.153151
BTN 109.628664
BWP 15.63742
BYN 3.410563
BYR 22635.15384
BZD 2.319233
CAD 1.618125
CDF 2611.126427
CHF 0.932311
CLF 0.026733
CLP 1055.559908
CNY 7.795147
CNH 7.793913
COP 3675.544784
CRC 522.915026
CUC 1.154855
CUP 30.603652
CVE 110.186265
CZK 24.201154
DJF 205.338828
DKK 7.47541
DOP 67.250199
DZD 153.530983
EGP 57.54318
ERN 17.322822
ETB 186.117873
FJD 2.553963
FKP 0.857848
GBP 0.857774
GEL 3.019946
GGP 0.857848
GHS 13.520339
GIP 0.857848
GMD 84.878181
GNF 10128.411837
GTQ 8.795715
GYD 241.227629
HKD 9.058306
HNL 30.907112
HRK 7.534038
HTG 150.767698
HUF 362.223087
IDR 20682.294394
ILS 3.477385
IMP 0.857848
INR 109.932764
IQD 1510.627108
IRR 1587694.361999
ISK 141.792902
JEP 0.857848
JMD 183.243508
JOD 0.818791
JPY 182.181232
KES 149.439303
KGS 100.991685
KHR 4673.518854
KMF 493.12343
KRW 1638.640772
KWD 0.357023
KYD 0.961017
KZT 541.135669
LAK 26067.486096
LBP 103263.512096
LKR 386.906578
LRD 208.141271
LSL 18.917964
LTL 3.409986
LVL 0.69856
LYD 7.339597
MAD 10.74762
MDL 20.03577
MGA 4908.365176
MKD 61.481068
MMK 2424.552772
MNT 4152.673297
MOP 9.316283
MRU 46.240358
MUR 54.209096
MVR 17.842347
MWK 1999.510632
MXN 19.917775
MYR 4.721853
MZN 73.807157
NAD 18.917964
NGN 1572.381111
NIO 42.438205
NOK 11.00856
NPR 175.401109
NZD 1.964222
OMR 0.444037
PAB 1.153176
PEN 3.903611
PGK 5.170149
PHP 70.148769
PKR 320.189388
PLN 4.30117
PYG 6876.93715
QAR 4.215887
RON 5.244777
RSD 117.358631
RUB 93.515578
RWF 1693.938243
SAR 4.333626
SBD 9.317771
SCR 16.99798
SDG 693.483603
SEK 10.953417
SGD 1.479663
SLE 28.408276
SOS 659.009126
SRD 43.501064
STD 23903.162464
STN 24.481764
SVC 10.089834
SZL 18.902002
THB 38.159872
TJS 10.643495
TMT 4.041992
TND 3.383582
TRY 54.964638
TTD 7.82126
TWD 37.289687
TZS 3055.166026
UAH 51.602087
UGX 4300.926733
USD 1.154855
UYU 46.366868
UZS 13708.204675
VES 871.004473
VND 30288.376519
VUV 137.825311
WST 3.151849
XAF 655.468764
XAG 0.018606
XAU 0.000271
XCD 3.121053
XCG 2.078224
XDR 0.815196
XOF 655.474435
XPF 119.331742
YER 273.556256
ZAR 18.867557
ZMK 10395.078432
ZMW 22.01327
ZWL 371.86277
  • RBGPF

    0.0000

    69.74

    0%

  • CMSC

    -0.0600

    21.73

    -0.28%

  • BTI

    0.1500

    59.27

    +0.25%

  • NGG

    -0.1600

    80.26

    -0.2%

  • GSK

    -0.0700

    51.46

    -0.14%

  • CMSD

    0.0200

    22.04

    +0.09%

  • BP

    -1.2300

    41.21

    -2.98%

  • RIO

    2.5000

    101.51

    +2.46%

  • RELX

    -0.1900

    36.61

    -0.52%

  • BCE

    0.0600

    22.06

    +0.27%

  • RYCEF

    0.6000

    21

    +2.86%

  • JRI

    -0.0500

    12.67

    -0.39%

  • BCC

    -1.6900

    84.8

    -1.99%

  • VOD

    -0.3800

    15.31

    -2.48%

  • AZN

    5.8800

    161.5

    +3.64%

Ketamine pill treats depression without psychedelic effects: study
Ketamine pill treats depression without psychedelic effects: study / Photo: Ed JONES - AFP/File

Ketamine pill treats depression without psychedelic effects: study

A new pill that slowly releases ketamine could treat people with severe depression without giving them the psychedelic side effects of the often-misused drug, early trial results suggested on Monday.

Text size:

First developed in the 1960s as an anaesthetic, ketamine's hallucinogenic and dissociative effects led to it becoming a party drug dubbed "Special K".

However, mounting research has demonstrated that ketamine is effective for the roughly quarter of people suffering from depression who see little benefit from common anti-depressant drugs.

In many countries, ketamine has been prescribed for depression for years.

US billionaire Elon Musk told CNN in March that he regularly uses a small amount of prescribed ketamine because it is "helpful for getting one out of the negative frame of mind".

The drug has long been administered intravenously in clinics, but more recently a nasal spray using a derivative called esketamine has increased in popularity.

Both can cause patients to have side effects such as dissociation, high blood pressure and an elevated heart rate.

There are also fears that medical use of the drug could slide into abuse.

The pill described in the journal Nature Medicine on Monday takes more than 10 hours to break down in the liver, lead study author Paul Glue told AFP.

"The really interesting feedback from patients is the lack of side effects -- no euphoria, no dissociation," said the researcher at New Zealand's University of Otago.

"I don't think these tablets would appeal to people who are abusing ketamine."

- Electro-shock alternative -

The phase 2 trial involved more than 270 people with depression who had previously tried an average of four different anti-depressant drugs.

More than half taking the ketamine pill went into remission for their depression, while 70 percent of the placebo group relapsed after 13 weeks, the study said.

Julaine Allan, an expert on mental health and addiction at Australia's Charles Sturt University who was not involved in the study, praised the trial while emphasising that more research is needed.

Ketamine does not work for everyone, and the "positive effects may wear off over time," she told AFP.

Michel Hoffmann, a psychiatrist at Geneva University Hospitals, said there is "real enthusiasm" in the medical community for ketamine's potential for treating depression.

"For patients who don't respond to conventional drugs, ketamine offers a way to avoid electro-shock therapy," he told AFP.

This last-resort treatment, which involves sending electric currents through the brain, has been proven to be effective.

But it can cause memory loss -- and some patients fear the procedure after seeing depictions of it in films such as "One Flew Over the Cuckoo's Nest".

- Fears of 'opioid style crisis' -

Some psychiatrists remain hesitant to prescribe ketamine for depression, fearing their patients could end up misusing the drug.

Last year, "Friends" actor Matthew Perry became the latest high-profile death from a ketamine overdose.

US police are investigating how Perry obtained the doses that caused his death -- he had reportedly not had a supervised infusion session for several days.

One potential benefit of quick-acting ketamine seen in previous research is that it could help patients considering suicide.

But there is "the plausible concern that the widespread use of ketamine might trigger a new opioid style crisis," Oxford researcher Riccardo De Giorgi said in a 2022 BMJ editorial.

By ridding ketamine of the side effects sought by some partygoers, the slow-release pill could alleviate some of these concerns.

There were still some side effects from the pill, the most common being headaches, dizziness and anxiety.

More research including phase 3 trials is needed before the drug can be reviewed by national medicine agencies, meaning it will be at least two or three years before patients could potentially access the pills, Glue said.

Y.Keller--NZN